Hugh A. Sampson

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

tandfonline.com Favicon

science.org Favicon

jimmunol.org Favicon

jacionline.org Favicon

annallergy.org + 2 more

Articles

Epicutaneous Immunotherapy with Viaskin Peanut in toddlers: a plain language summary

Dec 19, 2023 | tandfonline.com | David Stukus |Douglas Mack |Vivian P Hernandez-Trujillo |Hugh A. Sampson

Plain Language SummaryWhat is this summary about? This is a summary of an article published in The New England Journal of Medicine about the EPITOPE clinical study, which tested a skin patch called ViaskinTM Peanut 250 μg (micrograms) as a treatment option for peanut allergy in children aged 1 through 3 years.
Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects Aged 1-3 Years With and Without Concomitant Food Allergies in the EPITOPE Study

Feb 3, 2023 | jacionline.org | David Fleischer |Todd Green |Hugh A. Sampson |Jonas Meney

Cardiovascular Changes during Oral Food Challenge and Drug Provocation Test in Children Detected by Noninvasive Hemodynamic Monitoring

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →